NEW YORK (GenomeWeb News) – Single Cell Technology and AB Biosciences today announced a collaboration aimed at identifying therapeutic antibodies.

SCT will use its technology called Antibody Biologix to massively screen plasma cells and measure the kinetics of secreted antibodies. It also will use next-generation sequencing to sequence the cognate light and heavy chain mRNA.

ABB will select antibody targets, engineer protein antigens, and develop tools for characterizing antibodies identified by SCT.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.